Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol
Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol framework focused on consistent execution, practical monitoring, and safer progression.
Anti-inflammatory and joint-protective peptide protocol for ankylosing spondylitis targeting spinal inflammation, syndesmophyte prevention, and preservation of spinal mobility.
Who it's for
Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.
Free Peptide Guide
Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Protocol at a Glance
Cycle Duration
Continuous; minimum 24 weeks before assessing antibody response
Target Audience
AS patients with active disease, elevated CRP/ESR, and limited spinal mobility
| Compound | Dose | Frequency |
|---|---|---|
| VIP VIP — primary IL-17/Th17 suppressor, spinal inflammation control | 200 mcg SQ | Daily |
| BPC-157 BPC-157 — enthesitis repair, tendon-bone junction protection | 500 mcg | 2x daily |
| Thymosin Alpha-1 Thymosin Alpha-1 — regulatory T-cell restoration | 900 mcg SQ | 3x/week |
| MOTS-c MOTS-c — mitochondrial anti-inflammatory, joint oxidative stress reduction | 5 mg SQ | 3x/week |
Free Peptide Guide
Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Daily Schedule
Morning
Baseline review and first execution window
Log sleep, energy, and tolerance; complete planned VIP timing if scheduled.
Midday
Adherence and symptom check
Review hydration, workload, and side effects before any changes.
Evening
Recovery closeout and next-day setup
Record outcomes, maintain schedule consistency, and prepare next-day protocol.
Safety
- Escalating side effects or new concerning symptoms require prompt clinical review.
- Avoid abrupt multi-compound changes during unstable periods.
- Maintain regular follow-up with a licensed clinician throughout the cycle.
Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.
Who should avoid
- Anyone using this protocol without qualified medical supervision
- People with unstable medical or psychiatric conditions without specialist guidance
- Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Common Mistakes
Changing multiple variables at once
Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.
How to fix: Keep one-variable changes per review cycle and log response for several days.
Ignoring adherence and recovery fundamentals
Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.
How to fix: Protect daily anchors first, then optimize protocol details gradually.
FAQ
How long should Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol run before reassessment?
A common window is Continuous; minimum 24 weeks before assessing antibody response, with periodic review of tolerance and objective trends.
Can I increase complexity quickly for faster results?
Usually no. Safer optimization comes from staged changes and clear tracking.
What should I track each day?
Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.
Key Takeaways
- Consistency with VIP + BPC-157 execution matters more than frequent protocol changes.
- Single-variable adjustments improve safety and decision quality.
- Objective daily tracking supports better long-term outcomes.
Why This Stack Works
AS is driven by IL-17/IL-23 axis hyperactivation with HLA-B27-associated enthesitis and progressive spinal fusion. VIP is the most potent peptide suppressor of IL-17/Th17 responses. BPC-157 addresses enthesitis and tendon-to-bone junction inflammation. Thymosin Alpha-1 restores regulatory immune balance. MOTS-c reduces oxidative-driven inflammatory signaling in vertebral joints.
Clinical Research
No clinical references were provided for this stack yet.
More Immune Support Stacks
Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol
An adjunctive protocol for individuals with ankylosing spondylitis and axial spondyloarthropathy, targeting the IL-17/IL-23-driven enthesitis, progressive syndesmophyte formation, and the TNF-driven inflammatory cascade that cause irreversible spinal fusion.
Crohn's Disease & IBD Management Protocol
Peptide-based protocol targeting intestinal inflammation, barrier repair, and mucosal immune regulation for Crohn's disease and ulcerative colitis management.
Endometriosis & Pelvic Pain Management Protocol
Multi-mechanism peptide protocol for endometriosis addressing peritoneal inflammation, lesion-driven angiogenesis, central sensitization pain, and immune dysregulation underlying the disease.
Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.
Free Peptide Guide
Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.